Alnylam Pharmaceuticals | ALNY - Operating Profit


Alnylam Pharmaceuticals reported $112.6M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Incyte USD 700.4M 376.22M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.24B 171M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.27B 771M Mar/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Takeda JPY 201.42B 215.04B Jun/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026